While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

researchers recommended that people who received it get a second booster dose with an mRNA vaccine such as Moderna and Pfizer. According to the published results, there were 129 coronavirus ...

Concerns about the COVID-19 shots have increased after a report that drug maker Moderna failed to inform the U.S. government ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

The U.S. government has handed Moderna almost $600 million to accelerate its work on various bird flu vaccines as well as work on mRNA vaccines for other influenza strains with pandemic potential.

Erica Denhoff / Icon Sportswire via Getty Images Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu. The biotech ...

Under the resulting agreement, 17 participating countries can access Moderna's mRNA COVID-19 vaccine for up to four years. "This agreement presents an opportunity for Moderna to support and ...

including an extensive pipeline of therapeutics in clinical trials that could be the booster shot the stock needs to generate a rebound. Let's discuss the pros and cons of buying Moderna stock.